Lyon Street Capital’s OptimizeRx OPRX Stock Holding History

Lyon Street Capital’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-9,000	Closed	-$559K	–	98
2021 Q4	$559K	Buy	+9,000	New	+$682K	0.56%	85

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Lyon Street Capital's OPRX Position: Q1 2022 in Review

Lyon Street Capital sold out of OptimizeRx (OPRX) in Q1 2022, closing a stake of 9,000 shares — an estimated $559K sold.

Lyon Street Capital first reported a position in OPRX in Q4 2021 and held it in 1 quarter. The position peaked at $559K in Q4 2021. 153 funds tracked by Wall St. Rank hold OPRX as of Q1 2022.

Lyon Street Capital reported no remaining OptimizeRx position as of Q1 2022 after selling out during the quarter.
Lyon Street Capital sold 9,000 OptimizeRx shares in Q1 2022, an estimated $559K.
Lyon Street Capital first reported a position in OptimizeRx in Q4 2021 and held it in 1 quarter.
Lyon Street Capital's OptimizeRx position peaked at $559K in Q4 2021.
153 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2022.

Based on Lyon Street Capital's 13F filing for Q1 2022, filed 16 May 2022.